Telos Corporation
NASDAQ:TLSInformation Technology Services
-$0.01 today
- Market cap
- $511.05M
- Beta
- 0.97
- P/E (TTM)
- -12.4
- EPS (TTM)
- -$0.35
Volume 1.04M
Average 0.87M
TLS EBITDA Margin
EBITDA as a percentage of revenue.
Telos CorporationNASDAQ: TLS
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin widens to 11.7%
EBITDA Margin was 11.7% in Q1 FY2026, up 31.7 pp from a year earlier. On a trailing-twelve-month basis it was -7.4%, up 31.1 pp year over year. Over 3 fiscal years it widened by 6.2 pp.
Context
- EBITDA Margin widened in 2 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 5 analysts of 18.1% for the fiscal year ending Dec 2026, up from -15.3% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- 11.7%+40.5 pp QoQ
- Last fiscal yearDec 2025
- -15.3%+21.6 pp YoY
- LTMMar 2026
- -7.4%+31.1 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +31.7 pp | +30.3 pp | -1.4 pp |
| 1 year | +21.6 pp | +33.4 pp | +11.7 pp |
| 3 years | +6.2 pp | +39.7 pp | +33.5 pp |
| 5 years | — | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -15.3%
- Year-over-year change
- +21.6pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -15.3% | +21.6pp |
| FY2024 | 2024-12-31 | -36.9% | -20.3pp |
| FY2023 | 2023-12-31 | -16.6% | +4.9pp |
| FY2022 | 2022-12-31 | -21.5% | -6.3pp |
| FY2021 | 2021-12-31 | -15.2% | — |
EBITDA Margin vs competitors
How TLS compares with its peers on the latest reported figures
- TLS's LTM Mar 2026 EBITDA Margin of -7.4% is the lowest of the 9 companies compared; the peer median is 11.4%.
- Its year-over-year change of +31.1 pp is the 2nd highest of 9, against a peer median of -0.6 pp.
- Over three fiscal years its change of +6.2 pp compares with a peer median of +1.5 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 24.3% | -0.9 pp | +29.6 pp | |
| LTM Mar 2026 | 20.1% | -3.8 pp | +0.3 pp | |
| LTM Mar 2026 | 12.5% | +152.4 pp | +53.7 pp | |
| LTM Mar 2026 | 12.1% | -0.2 pp | +3.7 pp | |
| LTM Mar 2026 | 10.6% | -2.6 pp | -10.6 pp | |
| LTM Mar 2026 | 7.8% | +2.0 pp | +2.1 pp | |
| LTM Mar 2026 | 6.8% | -1.2 pp | -5.3 pp | |
| LTM Mar 2026 | 2.4% | +14.2 pp | +0.8 pp | |
| LTM Mar 2026 | -7.4% | +31.1 pp | +6.2 pp | |
NBPNovaBridge Biosciences | FY2025 | — | — | — |
| Peer median (excluding TLS) | 11.4% | -0.6 pp | +1.5 pp | |
Competitors are the stored peer set for TLS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 242.43M | 216.89M | 145.38M | 108.27M | 164.81M |
| Cost of Revenue | 156.4M | 137.84M | 92.44M | 73.84M | 103.79M |
| Gross Profit | 86.03M | 79.04M | 52.94M | 34.43M | 61.02M |
| Gross Margin | 35.5% | 36.4% | 36.4% | 31.8% | 37.0% |
| Research & Development | 19.1M | 16.92M | 12.25M | 8.44M | 7.06M |
| Selling, General & Admin | 108.4M | 115.98M | 81.01M | 75.49M | 78.93M |
| Operating Expenses | 127.49M | 132.89M | 93.26M | 90.3M | 85.53M |
| Depreciation & Amortization | 5.62M | 5.89M | 9.43M | 11.87M | 11.45M |
| EBITDA | (36.76M) | (46.61M) | (24.17M) | (39.98M) | (25.21M) |
| EBITDA Margin | -15.2% | -21.5% | -16.6% | -36.9% | -15.3% |
| Operating Income | (41.46M) | (53.85M) | (40.32M) | (55.87M) | (24.47M) |
| Operating Margin | -17.1% | -24.8% | -27.7% | -51.6% | -14.8% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 777K | 874K | 786K | 644K | 553K |
| Other Income / Expenses | (1.7M) | 476K | 5.93M | 3.38M | (12.74M) |
| Income Before Tax | (43.16M) | (53.37M) | (34.39M) | (52.49M) | (37.21M) |
| Pre-Tax Margin | -17.8% | -24.6% | -23.7% | -48.5% | -22.6% |
| Income Tax Expense | (28K) | 54K | 36K | 26K | (663K) |
| Net Income | (43.13M) | (53.43M) | (34.42M) | (52.52M) | (36.55M) |
| Net Margin | -17.8% | -24.6% | -23.7% | -48.5% | -22.2% |
| EPS (Basic) | (0.65) | (0.79) | (0.50) | (0.73) | (0.50) |
| EPS (Diluted) | (0.65) | (0.79) | (0.50) | (0.73) | (0.50) |
| Weighted Avg Shares | 66.37M | 67.56M | 69.26M | 71.85M | 72.88M |
| Weighted Avg Shares (Diluted) | 66.37M | 67.56M | 69.26M | 71.85M | 72.88M |
Telos Corporation
NASDAQ:TLS
Intrinsic Alpha fair value
Locked
Current Price
$6.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.